Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
収録刊行物
-
- The Lancet Oncology
-
The Lancet Oncology 16 (3), 257-265, 2015-03
Elsevier BV